Emergent Biosolutions Inc. 8-K Filing
Ticker: EBS · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2025 |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Emergent Biosolutions Inc. (ticker: EBS) to the SEC on Nov 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (ange on which registered Common Stock, $0.001 par value per share EBS New York Stock).
How long is this filing?
Emergent Biosolutions Inc.'s 8-K filing is 2 pages with approximately 605 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 605 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-11-12 16:02:01
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
Filing Documents
- ebs-20251107.htm (8-K) — 29KB
- a11122025retirementofdrsul.htm (EX-99.1) — 5KB
- image2.jpg (GRAPHIC) — 7KB
- 0001367644-25-000204.txt ( ) — 191KB
- ebs-20251107.xsd (EX-101.SCH) — 2KB
- ebs-20251107_def.xml (EX-101.DEF) — 15KB
- ebs-20251107_lab.xml (EX-101.LAB) — 26KB
- ebs-20251107_pre.xml (EX-101.PRE) — 16KB
- ebs-20251107_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On November 12, 2025, the Company issued a press release regarding Dr. Sullivan's retirement, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in any such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Emergent BioSolutions Inc. on November 12 , 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: November 12, 2025 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer